2024
Strategies for isoniazid preventive therapy in HIV-positive patients who consume alcohol.
Savinkina A, Muyindike W, Hahn J, Emenyonu N, Fatch R, Ngabirano C, Adong J, Jacobson K, Linas B. Strategies for isoniazid preventive therapy in HIV-positive patients who consume alcohol. The International Journal Of Tuberculosis And Lung Disease 2024, 28: 335-342. PMID: 38961548, PMCID: PMC11875055, DOI: 10.5588/ijtld.23.0303.Peer-Reviewed Original ResearchConceptsIsoniazid preventive therapyTB preventive therapyTuberculin skin testPreventive therapyReport alcohol useAlcohol useHIV-positive patientsTB disease incidenceLiver enzyme monitoringLatent TB infectionTB burden settingsSkin testTB infectionBurden settingsConsuming alcoholTB diseaseTB riskWHO guidanceTherapyEnzyme monitoringPLWHIsoniazidEvaluate hepatotoxicityHepatotoxicity concernsAST/ALT
2023
1901. High Prevalence of Latent Tuberculosis Infection in a Malaysian Prison
Zhang L, Shenoi S, Kamarulzaman A, Dhaliwal S, Ahmad A, Altice F. 1901. High Prevalence of Latent Tuberculosis Infection in a Malaysian Prison. Open Forum Infectious Diseases 2023, 10: ofad500.1729. PMCID: PMC10677608, DOI: 10.1093/ofid/ofad500.1729.Peer-Reviewed Original ResearchLatent tuberculosis infectionPrevalence of LTBIRisk of LTBITB preventive therapyIndependent risk factorTuberculin skin testC-reactive proteinActive TBPreventive therapyTuberculosis infectionRisk factorsHigh prevalenceMultivariable logistic regressionOpioid use disorderRisk of hepatotoxicityChest X-rayDrug use historyPaucity of dataLTBI treatmentHCV infectionHepatitis CHepatitis BMedian ageBlood testsSkin testPerceived stigma related to TB preventive therapy
Palacios C, Hough M, Shrestha R, Moll A, Kompala T, Andrews L, Shenoi S. Perceived stigma related to TB preventive therapy. The International Journal Of Tuberculosis And Lung Disease 2023, 27: 209-214. PMID: 36855038, DOI: 10.5588/ijtld.22.0570.Peer-Reviewed Original ResearchConceptsTB preventative therapyTB preventive therapyAnonymous cross-sectional surveyBurden of TBCommunity-dwelling adultsRural South African communityCross-sectional surveyPreventive therapyMean agePreventative therapyEndemic settingsPatient's familyKruskal-Wallis testStigma scoresRural South AfricaPoisson regressionNovel interventionsSouth African communityTherapyLess stigmaDescriptive statisticsFamily membersStigmaTBTwo-factor solution
2022
Community-based referral for tuberculosis preventive therapy is effective for treatment completion
Shenoi S, Kyriakides T, Dokubo E, Guddera V, Vranken P, Desai M, Friedland G, Moll A. Community-based referral for tuberculosis preventive therapy is effective for treatment completion. PLOS Global Public Health 2022, 2: e0001269. PMID: 36962910, PMCID: PMC10021376, DOI: 10.1371/journal.pgph.0001269.Peer-Reviewed Original ResearchTreatment completionCommunity-based identificationPreventive therapyIndependent predictorsGovernment primary care clinicsMedian age 35 yearsCommunity-based referralsHigher treatment completionMedian CD4 countTB preventive therapyTB endemic regionsTuberculosis preventive therapyComparison groupPrimary care clinicsClinic-based careAge 35 yearsCBR groupTeam of nursesSix-month courseMedian CD4Oral isoniazidCD4 countHIV careNight sweatsCare clinicsEffect of patient-delivered household contact tracing and prevention for tuberculosis: A household cluster-randomised trial in Malawi
Kaswaswa K, MacPherson P, Kumwenda M, Mpunga J, Thindwa D, Nliwasa M, Mwapasa M, Odland J, Tomoka T, Chipungu G, Mukaka M, Corbett E. Effect of patient-delivered household contact tracing and prevention for tuberculosis: A household cluster-randomised trial in Malawi. PLOS ONE 2022, 17: e0269219. PMID: 36074775, PMCID: PMC9455850, DOI: 10.1371/journal.pone.0269219.Peer-Reviewed Original ResearchConceptsTB preventive therapyStandard of careHousehold contactsNational guidelinesTB participantsEligible TB patientsMonths of randomisationCluster-randomised trialTRIAL REGISTRATION NUMBERHousehold contact tracingAge 5 yearsLow-resource settingsTB diseaseTB patientsPreventive therapySecondary outcomesTB screeningPrimary outcomeSymptom screeningIntervention armTB diagnosisSymptom screenMAIN OUTCOMEHigh riskTriage toolAssessing the quality of tuberculosis care using routine surveillance data: a process evaluation employing the Zero TB Indicator Framework in Mongolia
Saranjav A, Parisi C, Zhou X, Dorjnamjil K, Samdan T, Erdenebaatar S, Chuluun A, Dalkh T, Ganbaatar G, Brooks MB, Spiegelman D, Ganmaa D, Davis JL. Assessing the quality of tuberculosis care using routine surveillance data: a process evaluation employing the Zero TB Indicator Framework in Mongolia. BMJ Open 2022, 12: e061229. PMID: 35973702, PMCID: PMC9386240, DOI: 10.1136/bmjopen-2022-061229.Peer-Reviewed Original ResearchConceptsPrimary health centersTB preventive therapyRoutine surveillance dataHealth centersHousehold contactsCohort studyPreventive therapyTB careTB dispensariesRetrospective cross-sectional cohort studyCross-sectional cohort studySurveillance dataActive TB treatmentGuideline-adherent careHealth system predictorsQuality of tuberculosisOdds of patientsHealth system factorsQuality improvement interventionsLow-quality careCare cascadeTB screeningTB treatmentTuberculosis careIndex patients
2020
Choice architecture-based prescribing tool for TB preventive therapy: a pilot study in South Africa
Caturegli G, Materi J, Lombardo A, Milovanovic M, Yende N, Variava E, Golub J, Martinson N, Hoffmann C. Choice architecture-based prescribing tool for TB preventive therapy: a pilot study in South Africa. Public Health Action 2020, 10: 118-123. PMID: 33134126, PMCID: PMC7577007, DOI: 10.5588/pha.20.0020.Peer-Reviewed Original ResearchIsoniazid preventive therapy prescriptionIsoniazid preventive therapyPrescribing toolsStreamlining documentationMixed-methods implementation studyIsoniazid preventive therapy implementationIsoniazid preventive therapy initiationSame-day antiretroviral therapyPrimary care clinicsAntiretroviral therapyTB preventive therapyPreventive therapyLimited management supportPatient-related factorsAntiretroviral therapy initiationCare clinicsProvider acceptanceImplementation studyQualitative interviewsWHO targetPrescribingPrescription dataPrescribed deviceStock-outsProviders
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply